Works matching IS 03407004 AND DT 2016 AND VI 65 AND IP 6
Results: 12
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 701, doi. 10.1007/s00262-016-1831-8
- By:
- Publication type:
- Article
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 651, doi. 10.1007/s00262-016-1826-5
- By:
- Publication type:
- Article
Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 689, doi. 10.1007/s00262-016-1828-3
- By:
- Publication type:
- Article
2′-5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 663, doi. 10.1007/s00262-016-1830-9
- By:
- Publication type:
- Article
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.
- Published in:
- 2016
- By:
- Publication type:
- Letter
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 727, doi. 10.1007/s00262-016-1836-3
- By:
- Publication type:
- Article
Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 715, doi. 10.1007/s00262-016-1837-2
- By:
- Publication type:
- Article
Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 741, doi. 10.1007/s00262-016-1841-6
- By:
- Publication type:
- Article
Strategies to genetically engineer T cells for cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 631, doi. 10.1007/s00262-016-1842-5
- By:
- Publication type:
- Article
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 753, doi. 10.1007/s00262-016-1843-4
- By:
- Publication type:
- Article
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors 'A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome'.
- Published in:
- 2016
- By:
- Publication type:
- Letter
Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 6, p. 677, doi. 10.1007/s00262-016-1824-7
- By:
- Publication type:
- Article